Key result
Pharmacological targeting of the TMEM16A channel provides potential therapeutic opportunities for diseases such as hypertension, stroke, and cystic fibrosis.
Why the study?
TMEM16A is involved in vital physiological functions and may offer therapeutic benefit in conditions like hypertension, stroke, and cystic fibrosis.
This review highlights the therapeutic potential of targeting the TMEM16A channel in diseases such as hypertension, stroke, and cystic fibrosis.
Advances TMEM16A targeting for hypertension and CF; leaves open clinical validation of modulators.
channel is involved in a variety of vital physiological functions and may be targeted pharmacologically for therapeutic benefit in diseases such as hypertension, stroke, and cystic fibrosis (CF). The determination of the TMEM16A structure and high-throughput screening efforts, alongside ex vivo and in vivo animal studies and clinical investigations, are hastening our understanding of the physiology and pharmacology of this channel. Here, we offer a critical analysis of recent developments in TMEM16A pharmacology and reflect on the therapeutic opportunities provided by this target.
No takes yet. Share an insight, caveat, or question.
Al‐Hosni et al. (2022) conducted a review in Hypertension, stroke, and cystic fibrosis. TMEM16A channel pharmacological targeting was evaluated. Pharmacological targeting of the TMEM16A channel provides potential therapeutic opportunities for diseases such as hypertension, stroke, and cystic fibrosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: